Skip to main content

clobetasol

Generic: CLOBETASOL PROPIONATE·Brand: BYQLOVI, Byqlovi, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE (EMOLLIENT), CLOBEX, CORMAX, Clobex, Clodan, EMBELINE, EMBELINE E, IMPEKLO, IMPOYZ, Impeklo, Impoyz, OLUX, OLUX E, Olux, TEMOVATE, TEMOVATE E, Temovate, Tovet

clobetasol: 2 clinical trials tracked.

clobetasol evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about clobetasol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Atopic Dermatitis

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9

NCT06504160Registry updated 2026-07-02·Phase 1
Recruiting

Primary endpoint: Time to the first Atopic Dermatitis (AD) flare.

InterventionalRandomizedquadruple86 targetStarted 2025-05Completion 2027-028 sites · United StatesNational Institute of Allergy and Infectious Diseases (NIAID)

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140Registry updated 2026-09-25·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 enrolledStarted 2024-02Completion 2030-0650 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC